Table 1.

OS, PFS and RR results according to antiangiogenic agents in second-line combination therapy

	Aflibercept	Bevacizumab	Ramuricumab
	VELOUR	TML ML18147	RAISE
OS (months)	13.5 vs 12.06	11.2 vs 9.8	13.3 vs 11.7
PFS (months)	6.9 vs 4.7	5.7 vs 4.1	5.7 vs 4.5
RR (%)	19% vs 11.1%	6% vs 4%	13% vs 13%